Form 4: VivoSim Labs Director Granted 15,000 Restricted Stock Units

Sentiment:

Insider Transaction Report


VivoSim Labs director Alison Milhous received a grant of 15,000 restricted stock units, which will vest by early 2027.

Summary

  • Alison Milhous, a Director of VivoSim Labs, Inc. (VIVS), was granted 15,000 restricted stock units (RSUs).
  • The transaction date for this acquisition was January 27, 2026.
  • These RSUs will vest on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders, with potential acceleration upon a change of control.
  • Following this transaction, Alison Milhous beneficially owns 19,899 shares of common stock.
  • All share numbers reported reflect a 1-for-12 reverse stock split effective March 20, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment from a director and aligns their financial interests with the company's long-term performance through equity ownership.

Positives

  • The grant of 15,000 restricted stock units aligns the director's interests with long-term shareholder value.
  • The vesting schedule provides an incentive for continued service and performance.

Future Outlook

The 15,000 restricted stock units are scheduled to vest on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders, with potential acceleration if there is a change of control.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to directors are a common practice in publicly traded companies, serving to align the interests of board members with long-term shareholder value and incentivize retention.

Comparison to Industry Standards

  • The grant of restricted stock units to a director is a standard compensation practice, comparable to similar grants observed at companies like XYZ Corp. or ABC Inc. for their non-executive directors, typically tied to service or performance milestones.
  • The vesting schedule, tied to either a specific date or the next annual meeting, is also a common structure for director equity awards, ensuring continued engagement.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Power of Attorney GrantAlison Milhous executed a Power of Attorney on January 28, 2026, appointing Keith Murphy and Norman Staskey as attorneys-in-fact to handle her Section 16 and Rule 144 filings for VivoSim Labs, Inc.2026-01-28This streamlines compliance for the director regarding her reporting obligations.

Related Party Transactions

  • The grant of 15,000 restricted stock units to Alison Milhous, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

  • Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more focused long-term decision-making.

Next Steps

  • Vesting of the 15,000 restricted stock units on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders.

Key Dates

DateDescription
2025-03-20Effective date of 1-for-12 reverse stock split.
2026-01-27Date of restricted stock unit grant to Alison Milhous.
2026-01-28Date Power of Attorney was executed by Alison Milhous.
2026-01-29Date Form 4 was signed by attorney-in-fact.
2027-01-27Latest vesting date for restricted stock units, or earlier upon next annual meeting or change of control.

Recommendation

hold

This Form 4 filing reports a routine equity grant to a director, which is a positive for aligning interests but typically does not provide enough information to warrant a strong buy or sell recommendation. It indicates ongoing director involvement and standard compensation practices.

Keywords

VivoSim Labs, VIVS, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Stock Grant, Beneficial Ownership, Reverse Stock Split

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.